Autres langues Pyxis Oncology, Inc.

Actions

PYXS

US7473241013

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
4,44 ^USD	+3,26 %		-1,99 %	+146,67 %

22/03	PYXIS ONCOLOGY, INC. : HC Wainwright toujours à l'achat	ZM
21/03	Pyxis Oncology, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pyxis Oncology : Stifel 2024 Virtual Targeted Oncology Forum	17/04
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28/03
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights	27/03
Health Care Up on Drug Sales Optimism -- Health Care Roundup	21/03
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023	21/03
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA	13/03
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA	13/03
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	13/03
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024	07/03
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting	05/03
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	27/02
Pyxis Oncology Announces $50 Million Private Placement	27/02
Pyxis Oncology Announces $50 Million Private Placement	27/02
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	26/02
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29/12
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29/12
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer	28/11
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	28/11
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pyxis Oncology, Inc.

Actions

PYXS

US7473241013

Autres langues

Filtres